Skip to search formSkip to main contentSkip to account menu

dotatate

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
Molecular radiotherapy using 177Lu-DOTATATE is a most effective treatment for somatostatin receptor–expressing neuroendocrine… 
Highly Cited
2018
Highly Cited
2018
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
BackgroundRecently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory approval. Dosimetry can be used to… 
2017
2017
Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study
IntroductionThe peptide receptor radionuclide therapy (PRRT) with 90Y and 177Lu is a form of molecular targeted therapy for… 
2016
2016
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
BackgroundTargeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide… 
2016
2016
Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume
BackgroundSomatostatin analogue-based radionuclide therapy with 177Lu-DOTATATE is an important treatment option for patients with… 
Highly Cited
2013
Highly Cited
2013
Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
Kidney dosimetry in 177Lu and 90Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is… 
2013
2013
Dosimetric Analyses of Kidneys, Liver, Spleen, Pituitary Gland, and Neuroendocrine Tumors of Patients Treated With 177Lu-DOTATATE
Objectives The aim of this work was to calculate the radiation absorbed dose to kidneys, liver, spleen, pituitary gland, and… 
Highly Cited
2012
Highly Cited
2012
Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and… 
Highly Cited
2011
Highly Cited
2011
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
We hypothesized that 68Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to therapy with a nonradioactive somatostatin… 
2011
2011
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
BACKGROUND The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)